High expression of any of the three upregulated PEG signatures in grade III glioma patients was associated with unmethylated MGMT (Fig. 6D) and to a lesser extent in the grade IV GBM and grade II glioma patients (Fig. S6B), supporting our data that upregulated PEG signatures are associated with a worse prognosis in grade III glioma patients. Here, MGMT is linked to central nervous system cancer.